RxDoctor Payments Data

Kerry Chamberlain, DO

Medical Oncology · Largo, FLNPI 1073502233

Payments from drug & device makers

$5,690in general payments, 2019–2025

Across 285 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$1K
  • Novartis$699
  • Gilead$389
  • AbbVie$370
  • Pfizer$367
  • E.r. Squibb & Sons, L.L.C.$288
  • plus $2K from 44 others

What the payments were for

  • Food & beverage$5,57798%
  • Education$1132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,690 in reported general payments places this provider in the 25th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida

Medicare billing

Part B allowed, 2024
$2,518,241
Medicare patients
683
Services billed
140,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide31$575,463
PomalystPomalidomide20$461,084
JakafiRuxolitinib Phosphate21$264,465
TagrissoOsimertinib Mesylate12$198,856
BrukinsaZanubrutinib12$177,176
LynparzaOlaparib17$131,984
EliquisApixaban62$50,554
XareltoRivaroxaban38$41,397
Deferasirox12$16,896
Anastrozole147$2,702
Tamoxifen Citrate14$1,322
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen31$1,146
Morphine Sulfate ErMorphine Sulfate21$796
Morphine Sulfate17$743
Dexamethasone18$702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$1,214$575,46331 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$288$461,08420 claims
AstraZenecaTagrisso, Lynparza$101$330,84029 claims
Incyte CorporationJakafi$111$264,46521 claims
Beigene USA, Inc.Brukinsa$16$177,17612 claims
PfizerEliquis$367$50,55462 claims
Johnson & JohnsonXarelto$90$41,39738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →